🔬💉 Vaccine Breakthroughs: Dengue Trial Milestone, Gonorrhoea Vaccine Rollout, mRNA Patent Ruling & More
This week’s Vaccine Research roundup brings you high-impact developments from across the globe—from major dengue trial milestones and first-in-world gonorrhoea vaccine distribution, to critical legal wins in mRNA tech, COVID-19 antibody setbacks, and next-phase breakthroughs in cancer vaccine development. Whether you’re working in clinical research, vaccine strategy, public health, or biotech innovation, these updates keep you informed and future-ready.
🔬 India reaches a critical milestone with over 70% enrollment in its Phase 3 dengue vaccine trial, DengiAll
🇬🇧 UK launches the world’s first gonorrhoea vaccine rollout targeting high-risk groups
⚖️ Moderna wins a landmark mRNA patent case against Pfizer/BioNTech in the UK
💰 Imunon halts its COVID-19 vaccine development amid funding challenges
🧪 Anixa & Cleveland Clinic prep for Phase 2 trials of a groundbreaking breast cancer vaccine
❌ AstraZeneca discontinues its monoclonal antibody program for COVID-19 in the U.S. due to lack of efficacy against current variants
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine innovations and global immunization progress
#VaccineResearch #DengueVaccine #GonorrhoeaVaccine #Moderna #mRNApatent #COVID19 #CancerVaccine #ClinicalTrials #Biotech #Immunization #PublicHealth #LucidQuest #Pharmaceuticals #HealthcareInnovation #GlobalHealth #InfectiousDiseases #LucidQuestUpdates #SubscribeNow